Antigonadotropins: a novel strategy to halt Alzheimer's disease progression.
A significant amount of research has been focused on the relationship between hormones and Alzheimer's disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimer's disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimer's disease. This review provides information supporting the "gonadotropin hypothesis," puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimer's disease, and discusses potential therapeutic anti-gonadotropin compounds.
Voyager Pharmaceutical Corporation, Raleigh, NC 27615, USA.
Christopher W
CW
Gregory
Craig S
CS
Atwood
Mark A
MA
Smith
Richard L
RL
Bowen
D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004358:Drug Therapy / Q000379:methods / Q000639:trends; D006065:Gonadotropins, Pituitary / Q000037:antagonists & inhibitors* / Q000097:blood; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological
D006065:Gonadotropins, Pituitary; D006727:Hormone Antagonists